A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’

Slides:



Advertisements
Similar presentations
Integrative Oncology Trials Lorenzo Cohen, PhD Director, Integrative Medicine Program.
Advertisements

Facon T et al. Proc ASH 2013;Abstract 2.
Overview of Methotrexate Clinical Evaluations Malcolm Smith, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute FDA Pediatric ODAC Meeting.
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.
Efficacy and Safety of Conatumumab Plus AMG 479 in Patients With Advanced Sarcoma S Chawla,1 AC Lockhart,2 N Azad,3 E Elez,4 F Galimi,5 N Baker,6 YJ.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Successful treatment of pediatric desmoid tumors using hydroxyurea Naomi Balamuth, M.D. Richard Womer, M.D. November 13, 2008.
Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer Prepared for: Agency for Healthcare Research and Quality (AHRQ)
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
Vincent Grégoire, Peter Levendag et. al. DELINEATION OF THE CTV IN THE N 0 NECK OF PATIENTS WITH HEAD & NECK SQUAMOUS CELL CARCINOMA. ANATOMICAL BOUNDARIES.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
Xeloda ® plus oxaliplatin: rationale in colorectal cancer (CRC)  Oxaliplatin is active in CRC, especially when combined with 5-FU/leucovorin (LV)  Superior.
Management of DCIS KWH Experience Dr. Carmen Ho.
Ischemic Heart Disease Following Left Breast Irradiation with Active Breathing Control (ABC): 10 year Outcomes and Risk Modeling Abstract 1027 Presenter:
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.
Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Adjuvant radiochemotherapy in head and neck tumors H. Christiansen and C. F. Hess Department of Radiotherapy Goettingen University.
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.
QUALITY of LIFE Head & Neck Cancer and Chemotherapy Lisa Licitra Head and Neck Medical Oncology Unit Istituto Nazionale Tumori Milano.
Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.
Mathematical Modelling within Radiotherapy: The 5 R’s of Radiotherapy and the LQ model. Helen McAneney 1 and SFC O’Rourke 1,2 1 School Mathematics and.
Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.
Hormone treatment combined with radiotherapy
Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-
Applying CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2) in a Pre- Hospital Wilderness Context Paul B. Jones PGY1.
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) second interim analysis in.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Combined Modality Treatment of Locally Advanced Prostate Cancer: Radiation Therapy (RT) with Concurrent Androgen Deprivation Therapy (ADT) Howard Sandler.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
R2 민준기 / 정재헌 교수님. Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT)
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
The use of Radiotherapy in Cancer.. What is radiotherapy? The treatment of cancer with ionising radiation is called Radiotherapy or Radiation Oncology.
Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.
SNDA ETHYOL FOR RADIATION INDUCED XEROSTOMIA.
방사선종양학과 - 혈액종양내과 Joint Conference 경희의료원 방사선종양학과 R4 공 문 규.
Geisler C et al. Proc ASH 2011;Abstract 290.
Pazopanib: the role in the treatment of mRCC
Palumbo A et al. Proc ASH 2012;Abstract 200.
Mitchell Hickman Head and Neck Specialist Radiographer
Maury S et al. Proc ASH 2015;Abstract 1.
Case presented by Dr Polkinghorn
Rosell R et al. Proc ASCO 2011;Abstract 7503.
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Badoux X et al. Proc ASCO 2010;Abstract 6508.
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Best Practices in Lymph Node Mapping and Localization: Melanoma
ML 291 Rev. A.
1Kantarjian HM et al. Lancet Oncol 2011;12:
Response Rates and Adverse Event Rates in Phase II Trial
Presentation transcript:

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’ Meeting March 4, 2011 M. Kay Garcia, LAc, DrPH M. D. Anderson Cancer Center Integrative Medicine

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer Primary Objective: Primary Objective: To determine whether or not acupuncture can symptomatically improve severe xerostomia (grade 2 or 3) due to head/neck radiotherapy. Secondary Objective: Secondary Objective: To explore the duration of response (up to a maximum of 12 weeks) in the subgroup of patients who report a response to the acupuncture intervention. To explore the duration of response (up to a maximum of 12 weeks) in the subgroup of patients who report a response to the acupuncture intervention.

Significance Over 35,000 new cases of oral cavity and pharyngeal cancers were diagnosed in the United States in Over 35,000 new cases of oral cavity and pharyngeal cancers were diagnosed in the United States in Over 7600 deaths 1 Over 7600 deaths 1 Approximately 80% of patients develop xerostomia after only a few weeks of treatment. 2 Approximately 80% of patients develop xerostomia after only a few weeks of treatment. 2 Radiation-induced xerostomia becomes chronic in almost 70% of patients. 2 Radiation-induced xerostomia becomes chronic in almost 70% of patients Jemal A, et al, CA Cancer J Clin 2009;59(4): Emami B, et al, Int J Radiat Oncol Biol Phys 1991; 21:109.

Xerostomia Radiation clearly damages salivary tissue Radiation clearly damages salivary tissue Damage at doses <50Gy may be partially reversible Damage at doses <50Gy may be partially reversible No evidence of reversibility at higher doses No evidence of reversibility at higher doses Reduced salivary flow typically begins during the first few days of treatment Reduced salivary flow typically begins during the first few days of treatment 80% decrease noted at 6 weeks 80% decrease noted at 6 weeks Other quantitative changes Other quantitative changes decrease in salivary pH, increase in viscosity, reduction of salivary constituents (immunoglobulins, buffering capacity, small organic molecules)

Salivary Flow Significant variation between individuals Significant variation between individuals Subjective sensation of dryness does not correlate well with measured flow rates Subjective sensation of dryness does not correlate well with measured flow rates FDA currently recognizes the subjective response as the primary benefit FDA currently recognizes the subjective response as the primary benefit 1. Screebny L, et al, Int Dent J 1992; 42: Fox PC. J Dent Res 1987; 66: 689.

Common Symptoms Xerostomia (dry mouth) can impart a profound impact on QOL for patients and lead to: Xerostomia (dry mouth) can impart a profound impact on QOL for patients and lead to: taste aberrations loss of appetite dysphagia & odynophagia difficulty speaking difficulty sleeping irreversible nutritional deficits

Current treatment Rarely spontaneously improves by itself Rarely spontaneously improves by itself Current treatment: Current treatment: pilocarpine, amifostine saliva substitutes IMRT – still results in xerostomia palliative for symptom relief Low success rate or low acceptance

Acupuncture Traditional Chinese Medicine Theory Traditional Chinese Medicine Theory Excess vs Deficiency Heat Syndrome Excess vs Deficiency Heat Syndrome Yin Deficiency Syndrome Yin Deficiency Syndrome Lung Lung Stomach Stomach Kidney Kidney

Proposed Putative Mechanisms Increase in local blood flux Increase in local blood flux Increased production of neuropeptides such as calcitonin gene-related peptide (CGRP), vasoactive intestinal polypeptide (VIP) Increased production of neuropeptides such as calcitonin gene-related peptide (CGRP), vasoactive intestinal polypeptide (VIP) 1. Dawidson I, et al, Neuropeptides 1999; 33: Dawidson I, et al, Neuropeptides 1998; 32: Blom M, et al, J Oral Rehabil 1993; 20: 541.

Previous Studies of Acupuncture for Xerostomia Studies conducted by different investigators in the U.S. and Europe Studies conducted by different investigators in the U.S. and Europe Different points and techniques Different points and techniques Similar results Similar results -- improvement with 5-10 treatments -- improvement with 5-10 treatments -- benefits documented up to 3 years after treatment after treatment 1. Johnstone P, et al, Cancer 2002; 94: Rydholm M, Strang P. J Palliat Care 1999; 15: Blom M, et al, Oral Oncology, Eur J Cancer 1996; 32B: Andersen S, Machin D. Oral Oncol 1997; 33: Blom M. Lundeberg T. Oral Dis 2000; 6:15

Our Preliminary Studies Single-arm pilot (MDACC treatment) Single-arm pilot (MDACC treatment) 2-arm acu vs standard care (MDACC/Fudan, prevention) 2-arm acu vs standard care (MDACC/Fudan, prevention) 2-arm true acupuncture vs sham (MDACC/ Fudan, prevention) 2-arm true acupuncture vs sham (MDACC/ Fudan, prevention)

Single Arm Pilot (MDACC) Mean XI Scores Mean XI Scores (high score = increased severity) (0.0004) (0.0001)

Clinical Significance: XI Scores Partial response (PR) = difference > 6 points from baseline or 30% of starting score if baseline 6 points from baseline or 30% of starting score if baseline <20 Minor response (MR) = difference < 6 points but at least 3 points from baseline after 4 weeks of acupuncture Minor response (MR) = difference < 6 points but at least 3 points from baseline after 4 weeks of acupuncture No response (NR) = absence of PR or MR No response (NR) = absence of PR or MR Expected response rate = 40% Expected response rate = 40% Actual response rate = 44% at week 4 and 56% at week 8 Actual response rate = 44% at week 4 and 56% at week 8

Acupuncture vs Standard Care Prevention Trial 15 SYMPTOMSSALIVA FLOW

Acupuncture vs Standard Care Prevention 16 SYMPTOMSSALIVA FLOW

17 Placebo Controlled PreventionTrial

18 Development of Xerostomia Main Study Placebo Study

CCOP Study Design (Treatment) 3 groups 3 groups 1) Standard Oral Hygiene 2) Standard Oral Hygiene + True acupuncture twice weekly for 4 weeks weekly for 4 weeks 3) Standard Oral Hygiene + Sham acupuncture twice weekly for 4 weeks weekly for 4 weeks Follow-up Follow-up If PR or NR, follow-up at 8 and 12 weeks If MR, continue assigned treatment twice weekly for 4 weeks

Eligibility Inclusion Criteria Inclusion Criteria  Head/neck cancer  Received bilateral RT & developed xero of at least grade 2 or 3  Completed RT at least 9 months prior  Acupuncture naïve  Chemo during or subsequent to RT is allowed (& expected)  No hx of xero prior to RT  No active infection Exclusion Criteria Exclusion Criteria  Patients on or planned to receive another xero treatment agent (all other xero tx stopped at least 14 days prior to enrollment)  Previous acupuncture  Local infection  Hx of xero prior to head/neck RT

True Acupuncture Treatment Body points Body points CV 24, Lu7, K6, LI1-prime CV 24, Lu7, K6, LI1-prime Gb32 (placebo needle) Gb32 (placebo needle) Ear points Ear points Shenmen, Point zero, Shenmen, Point zero, Salivary Gland 2-prime Salivary Gland 2-prime

Sham Acupuncture Treatment Body points Body points Sham 1 chin; Sham 2,3 BUE; Sham 4-BLE; 1 penetraing needle at Gb32 right knee Sham 1 chin; Sham 2,3 BUE; Sham 4-BLE; 1 penetraing needle at Gb32 right knee Ear points Ear points 3 points on the ear helix that are not electrodermally active 3 points on the ear helix that are not electrodermally active

Measures Subjective Subjective Xerostomia Questionnaire (XQ)Xerostomia Questionnaire (XQ) MDASI-HNMDASI-HN FACT-GFACT-G Acupuncture Expectancy Scale (AES)Acupuncture Expectancy Scale (AES)

Patient Response XQ scores at baseline and 4 weeks after beginning treatment XQ scores at baseline and 4 weeks after beginning treatment No response=xero worsens or no decrease in XQ from baselineNo response=xero worsens or no decrease in XQ from baseline Minor response = point decreaseMinor response = point decrease Partial response =20 points or more decrease from baselinePartial response =20 points or more decrease from baseline Complete response = XQ score of 10Complete response = XQ score of 10 Duration determined by XQ at 8 and 12 weeks Duration determined by XQ at 8 and 12 weeks At week 4, patients will be asked which group they think they were assigned At week 4, patients will be asked which group they think they were assigned

Training & Accrual Training of acupuncturists Training of acupuncturists 1 day training + materials 1 day training + materials Patient Recruitment Patient Recruitment Anticipate 150 enrolled Anticipate 150 enrolled

Resources National Institutes of Health (NIH). National Center for Complementary and Alternative Medicine (NCCAM). [Online]. National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) [Online]

Thank you! Coordinating Center: The University of Texas M. D. Anderson Cancer Center Community Clinical Oncology Program Research Base Program Research Base 1515 Holcombe Blvd, Unit 241 Houston, Tx fax Joseph Chiang, MD-Chair Mark Chambers, DMD-Co Chair Lorenzo Cohen, PhD M. Kay Garcia, LAc, DrPH David Rosenthal, MD Lynn Palmer, PhD